

## Δημοσιεύσεις

---

1. Kosmidis PA, Fountzilas G, Eleftheraki AG, Kalofonos HP, Pentheroudakis G, Skarlos D, Dimopoulos MA, Bafaloukos D, Pectasides D, Samantas E, Boukovinas J, Lambaki S, **Katirtzoglou N**, Bakogiannis C, Syrigos KN. Paclitaxel and gemcitabine versus paclitaxel and vinorelbine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group (HeCOG). *Ann Oncol.* 2011 Apr;22(4):827-34
  2. **Katirtzoglou N**, Gkiozos I, Makrilia N, Tsaroucha E, Rapti A, Stratakos G, Fountzilas G, Syrigos KN. Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study. *Clin Lung Cancer.* 2010 Jan;11(1):30-5
  3. Ralli M, Tourkantonis I, Makrilia N, Gkini E, Kotteas E, Gkiozos I, **Katirtzoglou N**, Syrigos K. Docetaxel plus gemcitabine as first-line treatment in malignant pleural mesothelioma: a single institution phase II study. *Anticancer Res.* 2009 Aug;29(8):3441-4
  4. Saif MW, Syrigos KN, **Katirtzoglou NA**. S-1: a promising new oral fluoropyrimidine derivative. *Expert Opin Investig Drugs.* 2009 Mar;18(3):335-48. doi: 10.1517/13543780902729412 . Review. Erratum in: *Expert Opin Investig Drugs.* 2011 Oct;20(10):1469
  5. Syrigos KN, **Katirtzoglou N**, Kotteas E, Harrington K. Adhesion molecules in lung cancer: implications in the pathogenesis and management. *Curr Pharm Des.*2008;14(22):2173-83. Review
-